CD8A and neoplasm: FTY720 administration successfully blocked the CP1-dependent increase in both CD8 and CD4 TILs (Fig. 7a–d), and, consequently, reversed the anti-tumor efficacy of CP1 + PD-1 combination therapy (Fig. 7e, f).